Herantis Pharma Extends HER-096 Phase 2 Placebo-Controlled Treatment to Nine Months
Herantis Pharma is extending the placebo-controlled treatment period in the HER-096 Phase 2 study to nine months.
Herantis Pharma is extending the placebo-controlled treatment period in the HER-096 Phase 2 study to nine months.